Special Issue

Imaging and Molecular Biology as Biomarkers for Lung Cancer

Message from the Guest Editors

Dear colleagues, In the last decade, several developments and discoveries have completely changed the landscape of lung cancer management. Despite that, lung cancer still represents an unfavorable malignancy, with only about one-fifth of patients still alive five years after diagnosis. In this context, precision medicine is recognized as an approach that could provide far more tailored treatments. This concept in the field of cancer is known as precision oncology and requires the molecular profiling of tumors but can be used also in the context of imaging (both Radiology and Radiation Oncology). These two components are pivotal in the field of lung cancer, as both can provide useful biomarkers to improve the therapeutic ratio of lung cancer patients in all the stages of disease. Therefore, this Special Issue will focus on both the components of precision oncology (imaging and molecular biology). For this Special Issue, we welcome basic translational and clinical research papers, cancer biomarkers, professional opinions and reviews investigating the broad role of Molecular Biology and Imaging in the Clinical Management of Lung Cancer.

Guest Editors

Prof. Dr. Salvatore Cappabianca

Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy

Dr. Umberto Malapelle

Department of Public Health, University of Naples Federico II, Naples, Italy

Deadline for manuscript submissions

closed (30 September 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/146596

Cancers MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cancers@mdpi.com

mdpi.com/journal/

cancers







an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



cancers



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)